Drug intelligence / Profile preview

glibenclamide + metformin + olmesartan

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

A combination medication containing glibenclamide (a sulfonylurea), metformin (a biguanide), and olmesartan (an angiotensin II receptor blocker). This combination is used to treat patients with both type 2 diabetes and hypertension. Glibenclamide stimulates insulin secretion, metformin improves insulin sensitivity and reduces glucose production, while olmesartan helps control blood pressure.

Other names: glyburide + metformin + olmesartan

Targets

SUR2A (ATP-binding cassette sub-family C member 9)AGTR1 (Angiotensin II Type-1 receptor)ND1 (Mitochondrial electron transport chain complex I)SUR1 (Sulfonylurea receptor 1)

Beyond the preview

Go deeper on glibenclamide + metformin + olmesartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glibenclamide + metformin + olmesartan.

Explore the full profile